Business Description
CASI Pharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US14757U1097
Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.06 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 1.2 | |||||
Debt-to-EBITDA | -0.68 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -15.41 | |||||
Beneish M-Score | -5.97 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.8 | |||||
3-Year EBITDA Growth Rate | 17.2 | |||||
3-Year EPS without NRI Growth Rate | 15 | |||||
3-Year FCF Growth Rate | 26 | |||||
3-Year Book Growth Rate | -35 | |||||
Future 3-5Y Total Revenue Growth Rate | 35.6 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 65.55 | |||||
9-Day RSI | 65.98 | |||||
14-Day RSI | 66.66 | |||||
6-1 Month Momentum % | -48.78 | |||||
12-1 Month Momentum % | 46.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.05 | |||||
Quick Ratio | 3.25 | |||||
Cash Ratio | 2.3 | |||||
Days Inventory | 341.98 | |||||
Days Sales Outstanding | 127.89 | |||||
Days Payable | 77.43 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -19.13 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 58.36 | |||||
Operating Margin % | -94.08 | |||||
Net Margin % | -105.24 | |||||
FCF Margin % | -76.74 | |||||
ROE % | -108.6 | |||||
ROA % | -40.74 | |||||
ROIC % | -93.7 | |||||
ROC (Joel Greenblatt) % | -120.49 | |||||
ROCE % | -43.81 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.05 | |||||
PB Ratio | 5.74 | |||||
Price-to-Tangible-Book | 6.41 | |||||
EV-to-EBIT | -3.22 | |||||
EV-to-EBITDA | -3.22 | |||||
EV-to-Revenue | 3.03 | |||||
EV-to-Forward-Revenue | 4.43 | |||||
EV-to-FCF | -3.95 | |||||
Price-to-Net-Current-Asset-Value | 132 | |||||
Earnings Yield (Greenblatt) % | -31.06 | |||||
FCF Yield % | -25.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CASI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CASI Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 28.941 | ||
EPS (TTM) ($) | -2.29 | ||
Beta | 1.38 | ||
Volatility % | 117.47 | ||
14-Day RSI | 66.66 | ||
14-Day ATR ($) | 0.594843 | ||
20-Day SMA ($) | 6.104 | ||
12-1 Month Momentum % | 46.33 | ||
52-Week Range ($) | 1.9 - 8.48 | ||
Shares Outstanding (Mil) | 13.4 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CASI Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CASI Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
CASI Pharmaceuticals Inc Frequently Asked Questions
What is CASI Pharmaceuticals Inc(CASI)'s stock price today?
The current price of CASI is $6.60. The 52 week high of CASI is $8.48 and 52 week low is $1.90.
When is next earnings date of CASI Pharmaceuticals Inc(CASI)?
The next earnings date of CASI Pharmaceuticals Inc(CASI) is 2024-08-20.
Does CASI Pharmaceuticals Inc(CASI) pay dividends? If so, how much?
CASI Pharmaceuticals Inc(CASI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |